| http://www.w3.org/ns/prov#value | - Development of companion diagnostics has been supported by regulatory agencies, such as the FDA, which recently approved GlaxoSmithKline???s Tafinlar?? (dabrafenib), a BRAF inhibitor that targets a certain mutation in the BRAF gene, together with a companion diagnostic identifying patients having that specific mutation.
|
